Search Results
Sep 11, 2025, 08:00 ET PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
over 20 years of molecular testing for life sciences. They offer CAP/CLIA-certified and NYS-registered testing for CROs and clinical trial sponsors, an NGS Foundry for project-based sequencing with early technology access programs, and Quality Control testing for biomanufacturing and facility monitoring.
More news about: Carolina Molecular
Sep 10, 2025, 20:30 ET Wesbanco Announces Pricing of $230 Million Offering of Depositary Shares Representing Interests in Preferred Stock
WHEELING, W.Va., Sept. 10, 2025 /PRNewswire/ -- Wesbanco, Inc. (Nasdaq/NGS: WSBC) ("Wesbanco") today announced that it has priced an underwritten public offering of 9,200,000 depositary shares (the "depositary shares") each
More news about: WesBanco, Inc.
Sep 10, 2025, 16:12 ET Prinses Máxima Center for Pediatric Oncology implementiert Callisto™ von Volta Labs zur Rationalisierung klinischer Genomik-Workflows
Einführung von Callisto unterstreicht die weltweit wachsende Nachfrage nach Automatisierungslösungen, die die Effizienz, Genauigkeit und Skalierbarkeit von NGS verbessern. Über das Prinses Máxima Center for Pediatric OncologyDas Prinses Máxima Center for Pediatric Oncology in Utrecht,
More news about: Volta Labs Inc.
Sep 10, 2025, 16:06 ET Prinses Máxima Center for Pediatric Oncology met en œuvre Callisto™ de Volta Labs pour rationaliser les flux de travail en génomique clinique
L'adoption de Callisto souligne la demande mondiale croissante de solutions d'automatisation qui améliorent l'efficacité, la précision et l'évolutivité de la NGS. À propos du Prinses Máxima Center for Pediatric OncologyLe Prinses Máxima Center for Pediatric Oncology, situé à Utrecht,
More news about: Volta Labs Inc.
Sep 10, 2025, 15:14 ET El Centro Princesa Máxima de Oncología Pediátrica implementa Callisto™ de Volta Labs
adopción de Callisto subraya la creciente demanda global de soluciones de automatización que mejoren la eficiencia, la precisión y la escalabilidad de NGS. A erca del Centro Princesa Máxima de Oncología Pediátrica El Centro Princesa Máxima de Oncología Pediátrica, ubicado en
More news about: Volta Labs Inc.
Sep 10, 2025, 13:11 ET Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
bring insights to these patients faster." The adoption of Callisto underscores the growing global demand for automation solutions that improve NGS efficiency, accuracy, and scalability. About Prinses Máxima Center for Pediatric OncologyThe Prinses Máxima Center for Pediatric
More news about: Volta Labs Inc.
Sep 10, 2025, 13:11 ET Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
bring insights to these patients faster." The adoption of Callisto underscores the growing global demand for automation solutions that improve NGS efficiency, accuracy, and scalability. About Prinses Máxima Center for Pediatric OncologyThe Prinses Máxima Center for Pediatric
More news about: Volta Labs Inc.
Sep 10, 2025, 10:00 ET Avelo Airlines Orders up to 100 Embraer E195‑E2s to Modernize Fleet, Reduce Cost, and Fuel Growth
aircraft, making this a significant milestone for Embraer's flagship E2 program. The E195‑E2s will modernize Avelo's fleet, complementing its Boeing 737NGs for the foreseeable future while improving cost efficiency and network reach. The E2's excellent short-field performance, enabled by E2TS (Embraer
More news about: Avelo Airlines
Sep 10, 2025, 08:30 ET ePlus Acquires Assets of Realwave, Inc.
HERNDON, Va., Sept. 10, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Sep 09, 2025, 10:45 ET Molecular Diagnostics Market worth US$30.74 billion by 2030 with 9.6% CAGR | MarketsandMarkets™
Illumina, Inc. (US) Illumina, Inc. is prominent in the molecular diagnostics market, supported by its leadership in next-generation sequencing (NGS) technologies. The company has strategically accelerated its global expansion through targeted investments and partnerships in high-growth emerging markets.
More news about: MarketsandMarkets
Sep 09, 2025, 09:28 ET PANONY Appoints Sunny Ng as New CEO to Accelerate Globalization and Cross-Sector Innovation
and media organization, PANONY, owner of media platform PANews, officially announced Sunny Ng's appointment as CEO, entrusting her with full responsibility for corporate strategy and global business development. Sunny
More news about: PANews
Sep 09, 2025, 08:03 ET Solvias to Present at Cell & Gene Therapy International 2025 on Multilayered Quality Control in CGT Manufacturing
Company to showcase NGS-based GMP QC strategies during the conference presentation, highlighting advanced applications for robust QC in CGT KAISERAUGST, Switzerland, Sept.
More news about: Solvias
Sep 08, 2025, 10:44 ET SOPHiA GENETICS en Jessa Ziekenhuis kondigen samenwerking aan op het gebied van precisieoncologie tijdens het European Congress of Pathology
3.000 oncologische DNA- en RNA-monsters. Door deze samenwerking zal het ziekenhuis SOPHiA DDM™ gaan gebruiken voor alle pathologieactiviteiten om de NGS-workflows (next-generation sequencing) in één enkel platform samen te brengen. Deze volledige standaardisatie met universele bibliotheekvoorbereiding,
More news about: SOPHiA GENETICS
Sep 08, 2025, 10:41 ET SOPHiA GENETICS und Jessa Ziekenhuis verkünden Partnerschaft im Bereich der Präzisionsonkologie auf dem Europäischen Kongress für Pathologie
Rahmen dieser Zusammenarbeit wird das Krankenhaus SOPHiA DDM™ in seiner gesamten Pathologie einsetzen, um seine Next-Generation-Sequencing (NGS)-Workflows auf einer einzigen Plattform zu vereinheitlichen. Diese vollständige Standardisierung, die eine universelle Bibliotheksvorbereitung, einheitliche
More news about: SOPHiA GENETICS
Sep 08, 2025, 10:37 ET SOPHiA GENETICS et Jessa Ziekenhuis annoncent un partenariat en oncologie de précision au Congrès européen de pathologie
l'hôpital adoptera SOPHiA DDM™ dans l'ensemble de ses opérations de pathologie afin d'unifier ses flux de travail de séquençage de nouvelle génération (NGS) sous une plateforme unique. Cette normalisation complète, qui couvre la préparation universelle des bibliothèques, des protocoles automatisés unifiés
More news about: SOPHiA GENETICS
Sep 08, 2025, 10:33 ET Liquid Biopsy Market to Reach USD 30.65 Billion by 2035, with CAGR 9.41% Driven by Rising Cancer Burden and Demand for Non-Invasive Diagnostics - Vantage Market Research
of the market, highlighting its importance in non-invasive cancer diagnostics.Multi-Gene Parallel Analysis via Next-Generation Sequencing (NGS) dominated in 2024 with a 76.2% share, owing to its ability to simultaneously evaluate multiple genes with superior accuracy and efficiency.Cancer
More news about: Vantage Market Research
Sep 08, 2025, 09:32 ET Lancement d'Illumina® Protein Prep pour améliorer les connaissances protéomiques et faciliter les découvertes et le développement de médicaments
essai offrant des performances supérieures en matière de découverte protéomique à grande échelle reposant sur le séquençage de nouvelle génération (NGS).
More news about: Illumina, Inc.
Sep 07, 2025, 14:30 ET Illumina® Protein Prep, daha iyi ilaç keşfi ve geliştirilmesi için daha fazla proteomik içgörü sağlamak üzere piyasaya sürüldü
SAN DIEGO, 7 Eylül 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) bugün, yeni nesil sekanslama (NGS) tabanlı proteomik keşiflerinde üstün performans sunan Illumina Protein Prep testinin piyasaya sürüldüğünü duyurdu.
More news about: Illumina, Inc.
Sep 07, 2025, 14:26 ET Illumina® Protein Prep bringt neue Erkenntnisse aus der Proteomik für eine verbesserte Arzneimittelforschung und -entwicklung
von Illumina Protein Prep bekannt gegeben, einem Assay, der überlegene Leistung für die Proteomikforschung auf Basis von Next-Generation-Sequencing (NGS) in großem Maßstab bietet.
More news about: Illumina, Inc.
Sep 07, 2025, 03:22 ET Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
10.1097/JTO.0b013e3182779d18.26 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021;
More news about: Johnson & Johnson
Sep 06, 2025, 03:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
doi: 10.1097/JTO.0b013e3182779d18.30 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. 2021 World Conference on Lung Cancer Annual Meeting; January 29, 2021.31
More news about: Johnson & Johnson
Sep 05, 2025, 04:00 ET SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology
samples annually. Through this collaboration, the hospital will adopt SOPHiA DDM™ across its pathology operations to unify its next-generation sequencing (NGS) workflows under a single platform. This full standardization, covering universal library preparation, unified automated protocols, and a fully integrated
More news about: SOPHiA GENETICS
Sep 05, 2025, 04:00 ET SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology
samples annually. Through this collaboration, the hospital will adopt SOPHiA DDM™ across its pathology operations to unify its next-generation sequencing (NGS) workflows under a single platform. This full standardization, covering universal library preparation, unified automated protocols, and a fully integrated
More news about: SOPHiA GENETICS
Sep 04, 2025, 05:00 ET Rapid Food Safety Testing Market worth $31.22 billion by 2030 - Exclusive Report by MarketsandMarkets™
ensuring fast and accurate detection. Enzyme-Linked Immunosorbent Assay (ELISA) tests identify GMO-specific proteins, while next-generation sequencing (NGS) offers comprehensive monitoring. These methods help regulators and food companies verify compliance, labeling accuracy, and consumer safety. By
More news about: MarketsandMarkets
Sep 03, 2025, 15:28 ET Se lanza Illumina® Protein Prep para impulsar mayores conocimientos proteómicos
Protein Prep, un ensayo que ofrece un rendimiento superior para el descubrimiento proteómico a gran escala basado en secuenciación de próxima generación (NGS).
More news about: Illumina, Inc.